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AbsTrACT
Objective Myocardial ischaemia is a leading 
cause of acute heart failure (ahF). however, optimal 
revascularisation strategies in ahF are unclear. We aimed 
to compare two revascularisation strategies, coronary 
artery bypass graft (caBg) and percutaneous coronary 
intervention (Pci), in patients with ahF.
Methods among 5625 consecutive patients enrolled 
prospectively in the Korean acute heart Failure registry 
from March 2011 to February 2014, 717 patients who 
received caBg or Pci during the index hospitalisation 
for ahF were included in this analysis. We compared 
adverse outcomes (death, rehospitalisation for hF 
aggravation or cardiovascular causes, ischaemic stroke 
and a composite outcome of death and rehospitalisation 
for hF aggravation or cardiovascular causes) with the use 
of propensity score matching.
results For the propensity score- matched cohort 
with 190 patients, caBg had a lower risk of all- cause 
mortality than Pci (83 vs 147 deaths per 1000 patient- 
years; hr 0.57, 95% ci 0.34 to 0.96, p=0.033) during 
the median follow- up of 4 years. There was also a 
trend towards lower rates of rehospitalisation due to 
cardiovascular events or hF aggravation. subgroup 
analysis revealed that the adverse outcomes were 
significantly lower in the caBg group than in Pci group, 
especially in patients with old age, three- vessel diseases, 
significant proximal left anterior descending artery 
disease and those without left main vessel disease or 
chronic total occlusion.
Conclusions compared with Pci, caBg is associated 
with significant lower all- cause mortality in patients 
with ahF. Further studies should evaluate proper 
revascularisation strategies in ahF.
Clinical trial registration ncT01389843; results.
InTrOduCTIOn
Heart failure (HF) is a global health problem affecting 
about 26 million people worldwide.1 Although the 
aetiology of HF is diverse within and among world 
regions, coronary artery disease (CAD) is consis-
tently the predominant cause of HF, accounting for 
as much as 50% of HF cases.2–4 In those patients, 
revascularisation is generally accepted to improve 
clinical outcome.5–8 However, the time and choice 
of revascularisation are contentious.9 The condition 
is more complicated with acute heart failure (AHF), 
defined as a life- threatening medical condition with 
rapid onset or worsening of symptoms and/or signs 
of HF requiring urgent evaluation and treatment.10 
Most patients with HF experience episodes of AHF 
throughout the course of their disease and CAD is 
its leading precipitating factor,2 11 especially when 
the aetiology of HF is ischaemic heart disease.3 
Early revascularisation seems to improve clinical 
outcomes of those patients8 12 13 and current guide-
lines recommend an immediate invasive strategy 
with intent to perform revascularisation in patient 
with both AHF and acute coronary syndrome 
(ACS).14 15 However, the preferred strategy of 
revascularisation remains unclear.
Strategies for revascularisation in patients with 
multivessel CAD include percutaneous coronary 
intervention (PCI) and coronary artery bypass 
grafting (CABG). Which one is better has been long 
debated. Many trials comparing them have shown 
that the rates of most adverse clinical outcomes 
are lower after CABG than after PCI,16–21 thus 
the current guidelines recommend CABG as the 
preferred revascularisation strategy in patients 
with multivessel diseases.22 23 However, in these 
trials only a small portion of patients with chronic 
ambulatory HF with reduced left ventricular ejec-
tion fraction (LVEF) were included. Patients with 
severe congestive HF were excluded. In patients 
with AHF, especially that precipitated by ACS, the 
surgical risk might be higher than usual, and surgery 
might delay revascularisation. On the other hand, 
PCI may be related to additional risk for contrast- 
induced nephropathy and volume overload, which 
might complicate the clinician’s decision. Here, to 
investigate the better strategy for revascularisation 
in patients with AHF, we compared long- term clin-
ical outcome of the patients who received CABG or 
PCI during the hospitalisation for AHF with the use 
of propensity score matching.
MeTHOds
Patients, data collection and outcome
The Korean Acute Heart Failure registry is a 
prospective, multicentre, cohort study designed to 
describe demographic and clinical profiles, current 
diagnostic approaches and treatments and short- 
term and long- term patient outcomes of AHF in 
Korea. Detailed information on the study design 
and the main results has been described.2 3 Briefly, 
5625 patients hospitalised for AHF from 10 tertiary 
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university hospitals throughout the country were consecutively 
enrolled from March 2011 to February 2014. Among them, 717 
patients who received one of the two revascularisation strategies 
(590 PCIs and 127 CABGs) during the index hospitalisation were 
included in this analysis. Four patients who had rescue CABG 
immediately after PCI, because of complications of PCI, were 
excluded. Information on patient demographics, medical history, 
signs and symptoms, results of laboratory tests, ECG results, 
echocardiography results, coronary angiographic results, medi-
cations, procedures and outcomes at admission and discharge 
were included in this analysis. The primary end point was all- 
cause death after procedure or after discharge. The secondary 
outcome was rehospitalisation due to HF aggravation, rehos-
pitalisation due to cardiovascular causes, composite outcome 
of all- cause death and rehospitalisation due to cardiovascular 
causes or HF aggravation, length of hospital stay, in- hospital all- 
cause death, in- hospital cardiovascular death and stroke. Written 
informed consent was obtained from each patient at the early 
phase of this study; however, the institutional review boards 
at each hospital waived the requirement for informed consent 
because this study was initiated and sponsored by the Korean 
Ministry of Health and Welfare to improve public healthcare 
and had minimal risk for the patients.
statistical analyses
Descriptive statistics were used for clinical and laboratory char-
acteristics. Data are presented as numbers and percentages for 
categorical variables and mean±SD deviation for continuous 
variables. Baseline characteristics of the two intervention groups 
were compared with the independent t- test, or the Wilcoxon 
rank sum test for continuous variables as appropriate, and the Χ2 
test for categorical variables. To reduce the effect of treatment- 
selection bias and potential confounding in this observational 
study, we performed rigorous adjustment for significant differ-
ences in the baseline characteristics of patients with the use of 
propensity score matching.24 25 A propensity score for CABG 
versus PCI was calculated. The propensity score was estimated 
without regard to outcome variables using a logistic regression 
model. All prespecified covariates (table 1) were included in the 
final models for treatment with CABG versus PCI. A propensity 
score indicating the predicted probability of receiving a specific 
treatment conditional on the observed covariates was then calcu-
lated for each patient from the logistic equation. The predictive 
ability of the propensity score model was assessed using c- sta-
tistic (0.883). The p value of Hosmer and Lemeshow goodness- 
of- fit test was 0.9784. We created propensity score- matched 
pairs without replacement (1:1 match), and 95 patients with PCI 
and 95 patients with CABG were matched. After all the propen-
sity score matches were performed, we assessed the balance in 
baseline covariates between the two intervention groups with 
the paired t- test or the Wilcoxon signed rank test for continuous 
variables, and the McNemar's test or Bowker’s test of symmetry 
test for categorical variables and also with standardised differ-
ence. The risks of in- hospital all- cause death, cardiovascular 
death, stroke and the length of hospital stay were compared with 
the use of generalised estimating equations (GEE) treating each 
pair as a cluster. The postprocedure all- cause death or the post-
discharge risk for each outcome were compared with the use of 
Cox regression models considering the clustering effect based on 
robust sandwich covariance matrix estimate that accounted for 
the clustering of matched pairs. Survival curves were constructed 
with Kaplan- Meier estimates. All reported p values are two- sided 
and p<0.05 was considered to indicate statistical significance. 
SAS software, V.9.1, and the R programming language were used 
for statistical analyses. The statistical analyses were performed 
by professional statisticians affiliated to the Medical Research 
Collaborating Center at the Seoul National University College of 
Medicine and the Seoul National University Hospital.
resulTs
Patients and baseline characteristics
Between March 2011 and February 2014, 5625 patients 
were hospitalised for AHF at 10 tertiary university hospitals 
throughout Korea. Among them, 590 patients received PCI 
and 127 patients had CABG during the index hospitalisation. 
Drug- eluting stents were used in most PCI cases and 15 patients 
received bare- metal stents. The baseline clinical and coronary 
angiographic characteristics of the PCI and CABG groups are 
compared in table 1. Those who received CABG were younger, 
more likely to be male and to have diabetes, but were less likely 
to have hypertension and myocardial infarction. They had lower 
blood pressure, lower LVEF and higher serum creatinine levels 
at admission. Leucocytosis, hyponatraemia and high levels of 
natriuretic peptides were more prevalent in the CABG group. 
Furthermore, three- vessel diseases, left main lesion, proximal 
left anterior descending lesion and chronic total occlusion were 
more frequent in patients who received CABG. After propen-
sity score matching, there were 190 matched patients (table 1), 
and the distribution of propensity scores was essentially identical 
(see online supplementary figure 1). However, because the stan-
dardised differences for sex, New York Heart Association class, 
hypertension, diabetes, other intraventricular conduction delay, 
hyponatraemia, use of beta- blockers and number of diseased 
vessels were larger than 0.1, we adjusted for these variables in 
our final model.
Clinical outcomes
Table 2 presents the short- term and long- term clinical outcomes 
according to the treatment strategy in the overall and matched 
cohorts. In the overall cohort, in- hospital mortality rate was 
8.1% for the PCI group and 7.9% for the CABG group. The 
median follow- up duration for all- cause death was 1368 days for 
the PCI group and 1462 days for the PCI group in the overall 
cohort. The PCI group had 131 (95% CI 114 to 149) deaths 
per 1000 patient- years vs 81 (95% CI 56 to 113) in the CABG 
group (p=0.008). The unadjusted HR favoured the CABG 
group (0.62, 95% CI 0.44 to 0.90, p=0.011). Rehospitalisation 
for cardiovascular problems was 205 (95% CI 178 to 235) and 
144 (95% CI 102 to 198) per 1000 patient- years for the PCI 
and CABG groups, respectively (p=0.048). Rehospitalisation for 
HF aggravation was 117 (95% CI 98 to 139) per 1000 patient- 
years for PCI group and 91 (95% CI 59 to 133) for the CABG 
group (p=0.278). The unadjusted HRs for rehospitalisation for 
cardiovascular problems and HF aggravation were 0.76 and 
0.82, respectively, which was not significant. The repeat revas-
cularisation rate during follow- up was significantly lower in the 
CABG group than in the PCI group (HR 0.41, 95% CI 0.18 to 
0.94, p=0.035).
In the matched cohort, in- hospital mortality rate was 10.5% 
for the PCI group and 5.3% for the CABG group. The OR 
estimated by GEE was 0.47 (95% CI 0.15 to 1.50, p=0.203). 
ORs for in- hospital cardiovascular death and stroke were 0.37 
(95% CI 0.11 to 1.29, p=0.118) and 0.48 (95% CI 0.11 to 
2.06, p=0.325), respectively. Mean duration of hospital stay 
was 14 and 33 days for the PCI and CABG group, respectively 
(p<0.001) (table 2). The median follow- up duration after 
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Table 1 The baseline clinical and coronary angiographic characteristics
Overall cohort Propensity score- matched cohort
PCI group
(n=590)
CAbG group
(n=127) P values
standardised 
difference
PCI group
(n=95)
CAbG group
(n=95) P values
standardised 
difference
demographic characteristics
Age, years 70.7±11.4 68.3±10.6 0.018† 0.216 69.2±11.5 69.0±10.0 0.917‡ 0.015
Male 373 (63.2) 97 (76.4) 0.005 −0.290 78 (82.1) 70 (73.7) 0.201 0.204
Smoking 138 (23.4) 35 (27.6) 0.319 −0.096 23 (24.2) 24 (25.3) 1.000 −0.024
Body mass index, kg/m2 23.4±3.4 23.3±3.2 0.529† 0.018 23.4±2.9 23.3±3.3 0.719‡ 0.050
De novo HF 447 (75.8) 95 (74.8) 0.819 −0.022 67 (70.5) 69 (72.6) 0.871 0.047
Comorbidities
Hypertension 420 (71.2) 79 (62.2) 0.046 0.191 65 (68.4) 60 (63.2) 0.568 0.111
Diabetes 338 (57.3) 93 (73.2) <0.001 −0.340 61 (64.2) 68 (71.6) 0.360 −0.158
Myocardial infarction 410 (69.5) 63 (49.6) <0.001 −0.361 51 (53.7) 49 (51.6) 0.974 −0.021
Atrial fibrillation 113 (19.2) 25 (19.7) 0.890 −0.013 19 (20.0) 16 (16.8) 0.720 0.082
Chronic renal insufficiency 83 (14.1) 19 (15.0) 0.794 0.025 18 (19.0) 15 (15.8) 0.701 −0.083
Chronic lung disease 51 (8.6) 14 (11.0) 0.397 0.080 12 (12.6) 12 (12.6) 1.000 0
Cerebrovascular disease 90 (15.3) 18 (14.2) 0.757 −0.031 17 (17.9) 15 (15.8) 0.845 −0.056
History of malignancy 37 (6.3) 8 (6.3) 0.991 0.001 6 (6.3) 7 (7.4) 1.000 0.042
Clinical status
Systolic blood pressure 132.6±31.3 123.8±23.8 <0.001* 0.317 123.9±27.9 124.4±22.2 0.884‡ −0.021
Diastolic blood pressure 78.4±17.8 72.6±15.4 <0.001* 0.346 72.4±14.7 72.5±15.4 0.846§ −0.010
Pulse rate 91.8±23.8 93.0±21.7 0.753† −0.051 92.6±22.1 92.3±22.8 0.912‡ 0.015
NYHA functional class 0.2582 0.8516
  II 82 (13.9) 23 (18.1) 13 (13.7) 12 (12.6)
  III 171 (29.0) 41 (32.3) −0.072 30 (31.6) 35 (36.8) −0.111
  IV 337 (57.1) 63 (49.6) 0.151 52 (54.7) 48 (50.5) 0.084
Lung congestion 469 (79.5) 100 (78.7) 0.850 −0.018 74 (77.9) 74 (77.9) 1.000 0
laboratory test
LVEF, % 37.8±12.3 32.6±12.0 <0.001† 0.426 34.3±11.7 33.4±12.6 0.629‡ 0.073
Leucocytosis (WBC>10 000/mm3) 251 (42.5) 39 (30.7) 0.014 0.248 31 (32.6) 30 (31.6) 1.000 0.023
Hyponatraemia (<135 mmol/L) 89 (15.1) 30 (23.6) 0.019 0.217 79 (83.2) 75 (79.0) 0.597 0.108
Anaemia (haemoglobin<12 g/dL) 256 (43.4) 48 (37.8) 0.247 −0.114 54 (56.8) 56 (59.0) 0.885 −0.043
Serum creatinine, mg/dL 1.6±1.7 1.6±1.5 0.543† 0.050 1.7±1.4 1.6±1.7 0.214§ 0.039
BNP≥500 pg/mL or NT- proBNP≥1000, pg/mL 387 (65.6) 95 (74.8) 0.005 −0.202 69 (72.6) 70 (73.7) 0.902 −0.024
eCG
Q wave 162 (27.5) 44 (34.7) 0.104 0.156 32 (33.7) 33 (34.7) 1.000 0.022
Left bundle branch block 29 (4.9) 8 (6.3) 0.526 0.060 6 (6.3) 7 (7.4) 1.000 0.042
Right bundle branch block 39 (6.6) 14 (11.0) 0.085 0.156 8 (8.4) 8 (8.4) 1.000 0
Other intraventricular conduction delay 30 (5.1) 7 (5.5) 0.844 0.019 10 (10.5) 4 (4.2) 0.146 −0.244
Drug therapy before admission
  ACEIs or ARBs 177 (30.0) 60 (47.2) <0.001 0.360 41 (43.7) 41 (43.2) 1.000 0
  Beta- blockers 137 (23.2) 37 (29.1) 0.159 0.135 36 (37.9) 28 (29.5) 0.291 −0.179
  Aldosterone antagonists 40 (6.8) 17 (13.4) 0.013 0.221 10 (10.5) 12 (12.6) 0.824 0.066
Coronary lesions
Number of diseased vessels <0.001 0.726
  1 141 (23.9) 7 (5.7) 8 (8.4) 7 (7.4)
  2 212 (35.9) 13 (10.5) 0.632 9 (9.5) 13 (13.7) −0.132
  3 237 (40.2) 104 (83.9) −1.008 78 (82.1) 75 (79.0) 0.080
Left main lesion 81 (13.8) 44 (35.5) <0.001 −0.521 66 (69.5) 68 (71.6) 0.860 0.046
Proximal LAD lesion 339 (57.6) 92 (74.2) <0.001 −0.356 68 (71.6) 67 (70.5) 1.000 0.023
Chronic total occlusion 232 (39.3) 73 (58.9) <0.001 −0.399 52 (54.7) 49 (51.6) 0.761 0.063
Per cent (%) in parentheses.
*P value by independent t- test.
†P value by Wilcoxon rank sum test.
‡P value by paired t- test.
§P value by Wilcoxon signed rank test.
ACEIs, ACE inhibitors; ARBs, angiotensin receptor blockers; BNP, brain natriuretic peptides; CABG, coronary artery bypass graf; HF, heart failure; LAD, left anterior descending; LVEF, 
left ventricular ejection fraction; New York Heart Association; NT- proBNP, N- terminal pro brain natriuretic peptide; PCI, percutaneous coronary intervention; WBC, white blood 
cells. 
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Table 2 Clinical outcomes
Overall (n=717) Matched (n=190)
PCI CAbG P values PCI CAbG P values
Total, n 590 127 95 95
In- hospital outcomes
  Death 48 (8.1) 10 (7.9) 10 (10.5) 5 (5.3)
   CABG vs PCI, OR (95% CI) 0.9 (0.5 to 1.9) 0.849 0.47 (0.15 to 1.50) 0.203‡
  Cardiovascular death 46 (7.8) 7 (5.3) 10 (10.5) 4 (4.2)
   CABG vs PCI, OR (95% CI) 0.7 (0.3 to 1.5) 0.333 0.37 (0.11 to 1.29) 0.118‡
  Stroke 16 (2.7) 4 (3.1) 6 (6.3) 3 (3.2)
   CABG vs PCI, OR (95% CI) 1.1 (0.4 to 3.4) 0.830 0.48 (0.11 to 2.06) 0.325‡
  Hospital stay
   Mean±SE (95% CI), days 13.5±0.8 33.0±1.6 <0.001 14.4±1.5 32.9±3.4 <0.001‡
Follow- up time
  Total patient- years 1776 419 279 323
  Median, days
   Death 1368 1462 1383 1468
   Rehospitalisation for CV 489 977 375 966
   Rehospitalisation for HF aggravation 776 1080 714 1075
   Composite of death and CV rehospitalisation 734 1243 681 1238
   Composite of death and HF rehospitalisation 1153 1339 1258 1388
   Repeat revascularisation during follow- up 907 1171 767 1178
  Cumulative outcomes, n (%)
   Death 232 (42.8) 34 (29.1) 41 (48.2) 27 (30.0)
   Rehospitalisation for CV 203 (37.5) 38 (32.5) 37 (43.5) 30 (33.3)
   Rehospitalisation for HF aggravation 135 (24.9) 26 (22.2) 22 (25.9) 19 (21.1)
   Composite of death and CV rehospitalisation 341 (62.9) 55 (47.0) 59 (69.4) 44 (48.9)
   Composite of death and HF rehospitalisation 293 (54.1) 47 (40.2) 49 (57.7) 37 (41.1)
   Repeat revascularisation during follow- up 58 (10.7) 6 (5.1) 15 (17.7) 4 (4.4)
Main analysis, outcomes compared
  death
   Events per 1000 patient- years, n (95% CI) 131 (114 to 149) 81 (56 to 113) 0.008* 147 (105 to 199) 83 (55 to 121) 0.028*
   CABG vs PCI, HR (95% CI) 0.62 (0.44 to 0.90) 0.011 0.57 (0.34 to 0.96) 0.033†
  rehospitalisation for CV
   Events per 1000 patient- years, n (95% CI) 205 (178 to 235) 144 (102 to 198) 0.048* 261 (183 to 359) 151 (102 to 216) 0.026*
   CABG vs PCI, HR (95% CI) 0.76 (0.54 to 1.08) 0.129 0.67 (0.39 to 1.15) 0.146†
  rehospitalisation for HF aggravation
   Events per 1000 patient- years, n (95% CI) 117 (98 to 139) 91 (59 to 133) 0.278* 125 (79 to 190) 86 (52 to 134) 0.271*
   CABG vs PCI, HR (95% CI) 0.82 (0.54 to 1.25) 0.365 0.76 (0.40 to 1.44) 0.399†
  Composite of death and CV rehospitalisation
   Events per 1000 patient- years, n (95% CI) 268 (240 to 298) 170 (128 to 221) 0.001* 306 (233 to 395) 181 (132 to 243) 0.010*
   CABG vs PCI, HR (95% CI) 0.68 (0.51 to 0.90) 0.007 0.65 (0.42 to 1.01) 0.053†
  Composite of death and HF rehospitalisation
   Events per 1000 patient- years, n (95% CI) 198 (176 to 222) 132 (97 to 175) 0.008* 209 (155 to 76) 135 (95 to 186) 0.051*
   CABG vs PCI, HR (95% CI) 0.70 (0.51 to 0.95) 0.021 0.68 (0.43 to 1.07) 0.093†
  repeat revascularisation during follow- up
   Events per 1000 patient- years, n (95% CI) 46 (35 to 60) 18 (7 to 39) 0.021* 82 (46 to d135) 15 (4 to 40) 0.002*
   CABG vs PCI, HR (95% CI) 0.41 (0.18 to 0.94) 0.035 0.19 (0.06 to 0.60) 0.004†
*P value by exact Poisson test.
†P value by Cox regression models considering the clustering effect based on robust sandwich covariance matrix estimate that accounted for the clustering of matched pairs.
‡P value by generalised estimating equations treating each pair as a cluster.
CABG, coronary artery bypass graft; CV, cardiovascular; HF, heart failure, PCI,  percutaneous coronary intervention. 
discharge from index hospitalisation was 1383 days for the 
PCI group and 1468 days for the CABG group in the matched 
cohort. During the follow- up period, the PCI group had 147 
(95% CI 105 to 199) deaths per 1000 patient- years vs 83 (95% 
CI 55 to 121) in the CABG group (p=0.028) favouring CABG 
(HR 0.57, 95% CI 0.34 to 0.96, p=0.033) (figure 1A). The 
result was identical even when we estimated the mortality based 
on the date of revascularisation, but not based on the date of 
discharge (HR 0.54, 95% CI 0.35 to 0.85, p=0.008, figure 1B). 
Rehospitalisation for cardiovascular problems was 261 (95% CI 
183 to 359) and 151 (95% CI 102 to 216) per 1000 patient- 
years for the PCI and CABG groups, respectively (p=0.026). 
Rehospitalisation for HF aggravation was 125 (95% CI 79 to 
190) per 1000 patient- years for the PCI group and 86 (95% CI 
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Figure 1 Kaplan- Meier curves in the matched and overall cohorts. Long- term clinical outcomes in total population and in the matched cohort. 
(A) All- cause death after discharge. (B) All- cause death after the revascularisation procedure. (C) Rehospitalisation for cardiovascular problems. 
(D) Rehospitalisation for heart failure aggravation. (E) All- cause death and rehospitalisation for cardiovascular problems. (F) All- cause death and 
rehospitalisation for heart failure aggravation. CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
52 to 134) for the CABG group (p=0.271). HRs for rehospi-
talisation for cardiovascular problems and HF aggravation were 
0.67 (95% CI 0.39 to 1.15, p=0.146) and 0.76 (95% CI 0.40 
to 1.44, p=0.399), respectively (figure 1C,D). The unadjusted 
HRs for a composite outcome of death and rehospitalisation for 
either cardiovascular causes or HF aggravation were 0.65 (95% 
CI 0.42 to 1.01, p=0.053) and 0.68 (95% CI 0.43 to 1.07, p= 
0.093), respectively (figure 1E,F). The repeat revascularisation 
rate was 82 (95% CI 46 to 135) per 1000 patient- years for PCI 
group and 15 (95% CI 4 to 40) per 1000 patient- years for the 
CABG group (p=0.002). The unadjusted HR for repeat revascu-
larisation in the matched cohort was 0.19 (95% CI 0.06 to 0.60, 
p=0.004) (supplementary figure 2).
Since prescription of ACE inhibitors/angiotensin receptor 
blockers (ACEIs/ARBs), beta- blockers and aldosterone 
antagonists were not matched between the groups, there were 
significant differences in their use at discharge (table 3). ACEIs/
ARBs and beta- blockers were more frequently described in the 
PCI group compared with the CABG group (64.2% vs 43.2%, 
p=0.008 for ACEIs/ARBs; 63.2% vs 47.4%, p=0.082 for beta- 
blockers). After adjusting these variables, all- cause mortality after 
discharge and after the procedure remained significantly lower in 
the CABG group (HR 0.51, 95% CI 0.30 to 0.88, p=0.016 after 
discharge and HR 0.57, 95% CI 0.36 to 0.91, p=0.018 after 
procedure). Moreover, because there were several covariates 
with standardised differences larger than 0.1 even after propen-
sity score matching, aside from the drug therapies, we included 
these factors in the final Cox proportional HR model together 
with drug therapy at discharge. This analysis revealed that even 
after adjustment, CABG was still significantly associated with 
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Table 3 Drug therapy at discharge
Overall cohort Propensity score- matched cohort
PCI group
(n=590)
CAbG group
(n=127) P values
standardised 
difference
PCI group
(n=95)
CAbG group
(n=95) P values
standardised 
difference
Drug therapy at discharge
  ACEIs or ARBs 387 (65.6) 58 (45.7) <0.001 −0.409 61 (64.2) 41 (43.2) 0.008 −0.432
  Beta- blockers 382 (64.8) 59 (46.5) <0.001 −0.375 60 (63.2) 45 (47.4) 0.082 −0.322
  Aldosterone antagonists 200 (33.9) 58 (45.7) 0.012 0.242 36 (37.9) 42 (44.2) 0.480 0.129
Per cent (%) in parentheses.
ACEIs, ACE inhibitors; ARBs, angiotensin receptor blockers; CABG,  coronary artery bypass graft; HF,  heart  failure; PCI,  percutaneous coronary intervention. 
Figure 2 Interaction and HR for all- cause death after discharge in prespecified subgroups in the matched cohort. DM, diabetes mellitus; IHD, 
ischaemic heart disease; LAD, left anterior descending; LVEF, left ventricular ejection fraction.
decreased all- cause mortality after the procedure as well as after 
discharge in comparison to PCI (HR 0.53; 95% CI 0.31 to 0.90; 
p=0.020 for mortality after discharge and HR 0.45; 95% CI 
0.27 to 0.74; p=0.002 for mortality after the procedure).
subgroup outcomes
Subgroup analysis was performed to determine the impact of 
CABG on death according to the characteristics of the patients 
and the coronary lesions. Figure 2 and online supplementary 
figure 3 depict the HRs for mortality associated with CABG in 
clinically relevant prespecified subgroups and the p values for 
interaction between the revascularisation strategy and the covari-
ates. Although there were no significant interactions, lower risk 
with CABG was statistically significant, especially in elderly 
patients, those with three- vessel diseases, significant proximal 
left anterior descending artery disease and those without left 
main vessel disease or chronic total occlusion.
dIsCussIOn
In this propensity score- matched comparison between PCI 
and CABG in patients admitted for AHF, the rate of death 
from any cause over 4 years was lower by 40% among patients 
who underwent CABG than among those who received PCI. 
As anticipated, CABG was associated with longer hospital stay. 
Thus, to exclude bias from the time lag incurred by the further 
hospital stay in the CABG group, we analysed mortality based 
on the date of revascularisation instead of the date of discharge 
to yield identical results. Although there was no significant 
difference between the groups with respect to rehospitalisa-
tion for cardiovascular causes or for HF aggravation, there 
was a trend favouring CABG over PCI across all clinically rele-
vant outcomes we evaluated. We believe the numbers of cases 
and controls or the follow- up duration were not enough to 
show a statistical significance for the secondary outcomes. The 
divergence of the curves over the period of follow- up supports 
our hypothesis and underscores the lasting benefits of CABG 
over PCI.5 6
In the overall cohort, CABG was associated with lower LVEF 
and severe coronary lesions as expected. Thus, the characteris-
tics of the patients in the matched cohort were similar to those 
of CABG group in the overall cohort, showing lower LVEF 
and severe coronary lesions. Although there was no interac-
tions among the subgroups, the benefit of CABG was associ-
ated with the extent of CAD. This is consistent with previous 
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reports, which indicated a greater benefit of CABG in patients 
with three- vessel CAD than among patients with one- vessel or 
two- vessel disease.16 19 21 26 This might be attributable to the 
different ability of each revascularisation strategy to achieve 
complete revascularisation in extensive CADs as some believe 
that late outcome is influenced by the completeness of revas-
cularisation but not by the method.27 The complete revas-
cularisation rate, defined as all stenotic main- branch vessels 
being revascularised,28 was significantly higher in the CABG 
group than in the PCI group in our matched cohort (72.4% 
vs 43.5%, p<0.001). Although the adverse outcomes were 
significantly lower in the CABG group than in the PCI group, 
especially in more elderly patients, those with significant prox-
imal left anterior descending artery disease, and those without 
left main vessel disease or chronic total occlusion, the trends 
were similar all favouring CABG than PCI, and the statistical 
significance was related to the number of patients and events.
A recent report by the Surgical Treatment for Ischaemic 
Heart Failure trial supported the decision for revascularisation 
in patients with CAD associated with left ventricular dysfunc-
tion. However, there were few direct comparisons between 
PCI versus CABG in patients with left ventricular dysfunc-
tion. In an analysis from a cohort of patients who received 
revascularisation and had a history of HF, patients undergoing 
CABG appeared to have slightly better survival than those who 
received PCI.29 However, this cohort was not intended to enrol 
patients with HF but rather patients who received coronary 
angiography, and the patients were selected based on history 
of HF. Therefore, only 7.7% of those who received revascu-
larisation had HF as the primary indication for catheterisation. 
The Heart Failure Revascularisation trial evaluated whether 
revascularisation improves the survival of patients with HF 
due to CAD.30 Patients with LVEF <35% requiring chronic 
diuretic therapy and with evidence of at least five segments 
being affected by ischaemia and/or hibernation were included. 
Any conventional revascularisation strategy was permitted. 
However, only 138 of the planned 800 patients were enrolled 
owing to problems with recruitment and funding, and the 
study was stopped early. There were no differences in the inci-
dence of all- cause mortality and in quality of life. Therefore, 
this is the first analysis supporting the advantage of CABG 
over PCI for survival of the patients hospitalised for AHF with 
CAD, especially those with multivessel diseases.
lIMITATIOns
The major limitation of the present study is that it is an obser-
vational study. The revascularisation strategy was not based on 
randomised assignment and so is subject to potential bias with 
respect to the relative preprocedural severity of illness among 
patients treated with CABG and PCI. To minimise this bias, we 
used propensity score matching. Nevertheless, hidden bias may 
remain because of the influence of unmeasured confounders. 
For example, one might argue that those who received PCI 
represents ACS while CABG represents chronic ischaemic 
cardiomyopathy. However, after propensity score matching 
there were no significant difference between the groups in prev-
alence of myocardial infarction or ACS as an aetiology or aggra-
vating factor of HF, respectively (53.7% vs 51.6%, p=0.974, 
standardised difference=−0.021; 98.9% vs 93.7%, p=0.123, 
standardised difference=0.123). Even after propensity score 
matching, there were several covariates with standard differ-
ence exceeding 0.1. However, after adjustment of these factors, 
CABG was still significantly associated with decreased all- cause 
mortality compared with PCI. Another caveat is that our analysis 
was underpowered to detect significant differences in secondary 
outcomes like rehospitalisation. Finally, the characteristics of the 
matched population were similar to those of the CABG group 
in the overall cohort. Therefore, it would not be appropriate 
to apply our results to the general population with ischaemic 
heart disease presenting with AHF; instead, our results apply to 
patients with severe coronary lesions.
COnClusIOn
In a matched cohort of patient with AHF and CAD, CABG was 
associated with better long- term rate of all- cause death.
Key messages
What is already known on this subject?
 ► Revascularisation of coronary artery diseases improves 
clinical outcome of heart failure with ischaemic heart disease.
What might this study add?
 ► Compared with percutaneous coronary intervention, coronary 
artery bypass graft is associated with significant lower 
all- cause mortality in patients with acute heart failure (83 
deaths per 1000 patient- years in the coronary artery bypass 
graft group vs 147 deaths per 1000 patient- years in the 
percutaneous coronary intervention group (HR 0.57, 95% CI 
0.34–0.96, p=0.033), especially when they have multivessel 
coronary artery diseases (HR 0.46, 95% CI 0.26 to 0.81, 
p=0.008).
How might this impact on clinical practice?
 ► This result suggests that coronary artery bypass graft might 
be preferred in acute heart failure with multivessel coronary 
artery diseases.
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